The three asparaginases: Comparative pharmacology and optimal use in childhood leukemia

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 621-629

  Asselin, Barbara L ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Acute lymphoblastic leukemia; and drug resistance; Asparaginase; Childhood leukemia; Hypersensitivity; Pharmacology

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BLOOD; CHILD; COMPARATIVE STUDY; DRUG HYPERSENSITIVITY; ENZYMOLOGY; ERWINIA; ESCHERICHIA COLI; HUMAN; REMISSION;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; DRUG HYPERSENSITIVITY; ERWINIA; ESCHERICHIA COLI; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; REMISSION INDUCTION;

EID: 0032613231     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_69     Document Type: Article

References (20)

1. Broome JD. "Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects" Nature 1961, 191:1144-1115.
2. Killander D, Dohlwitz A, Engstedt L, Franzen S, Gahrton G, Gullbring B, Holm G, Holmgren A, Hoglund S, Killander A, Lockner D, Mellstedt H, Moe PJ, Palmblad J, Reizenstein P, Skarberg KD, Swedberg B, Uden AM, Wadman B, Wide L, Ahstrom L. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976, 37:220-228.
3. Land VJ, Shuster JJ, Pullen J, Harris M. Krance RA, Castleberry R, Akabutu J, Barbosa JL and Rosen D. Unexpectedly high incidence of allergic reactions with high dose weekly asparaginase consolidation therapy in children with newly diagnosed non-T, non-B acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Proc Am Soc Clin Oncol 1989, 8:215,A834.
4. Cheung NKV, Chau IY, Coccia PR Antibody response to Escherichia coli L-asparaginase. Am J Pediatr Hematol/Oncol 1986, 8(2):99-104.
5. Fabry U, Korholz D, Jurgens H, Gobel U, and Wahn V. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children - evidence of a complement-mediated mechanism. Pediatr Res 1985, 19:400-408.
6. Kurtzberg J, Asselin B, Pollack B, Bernstein M, Buchanan G, and the Pediatric Oncology Group. PEG L-asparaginase vs native E. coli asparaginase for reinduction of relapsed acute lymphoblastic leukemia: POG #8866 phase II trial. Proc ASOC 1993, 12:p325, 1079A.
7. Kurtzberg J, Asselin B, Poplack D, Grebanier A, Chen R, Franklin A, Scudiery D and Fisherman J. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy. Proc AACR 1993, 34:p304, 1807A.
8. Kurtzberg J, Asselin B, Pollack B, Ettinger L, Ravindranath Y, Faucey J and Fisherman J. PEG-L-asparaginase pharmacology in pediatric patients with acute lymphoblastic leukemia. Proc ASCO 1994, 13:p144, 370A.
9. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE and Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993, 11(9): 1780-1786.
10. Asselin BL, Lorenson My, Whitin JC, Coppola DJ, Kende AS, Blakley RL and Cohen HJ. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor. Cancer Res 1991, 51:6568-6573.
11. Abshire T, Pollock B, Billett A, Bradley P, and Buchanan G. Weekly polyethylene glycol conjugated L-asparaginase produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group Study 9310. Proc ASCO 1995, 14:p344, 1038A.
12. Jones B, Holland JF, Glidewell O, Jacquillat C, Weil M, Pochedly C, Sinks L, Chevalier L, Maurer HM, Koch Kjell, Falkson G, Patterson R, Seligman B, Sartorious J, Kung F, Haurani F, Stuart M, Burgert EO, Ruymann F, Sawitsky A, Forman E, Pluess H, Truman J, Hakami N. Optimal use of L-asparaginase (NSC - 109229) in acute lymphocytic leukemia. Med Pediatr Oncol 1977,3:387-400.
13. Ertel IJ, Nesbit ME, Hammond D, Weiner J, and Sather H. Effective dose of L-asparaginase for inductio of remission in previously treated children with acute lymphoblastic leukemia: A report for the Children's Cancer Study Group. Cancer Res 1979, 39:3893-3896.
14. Sallan SE, Hitchcok-Bryan S, Gelber R, Cassady JR, Frei III E, and Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983, 43:5601-5607.
15. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, and Sallan SE. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986, 315:657-663.
16. Boos J, Werber G, Verspolh E, Nowak-Goth U, Jurgens H. Asparagine levels in children on E. coli and Erwinia - asparaginase therapy. Haematol Blood Transfusion 37: Acute Leukemias V- Hiddemann et al (eds) Springer-Verlag Berlin Heidelberg, 1996, p67-69.
17. DiBenedetto SP, DiCataldo A, Ragusa R, Meli C and Lo Nigrio L. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. J Clin Oncol 1995, 13:339-344.
18. Ohnuma T, Holland JF, Freeman et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970, 30:2297-2305.
19. Capizzi RL, Bertino JR, Skeel RT, et al. Clinical, biochemical, pharmacological and immunological studies. Ann Intern Med 1971, 74:893-901.
20. Boos J, Nowak-Gottl U, Jurgens H, Fleischhack G, Bode U. Loss of activity of Erwinia asparaginase on repeat applications (Letter). J Clin Oncol 1995, 13:2474-2475.